MetaCap

Editas Medicine Financial Statements

NASDAQ: EDITHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.64-0.07 (-4.09%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Editas Medicine revenue and earnings

In fiscal 2025, Editas Medicine generated $40.5 million in revenue, up 25.4% from fiscal 2024. Editas Medicine reported a net loss of $160.1 million, compared with a loss of $237.1 million a year earlier. Operating margin was -394.9%.

Diluted earnings per share came in at -$1.80. Over the last 5 fiscal years, EDIT's revenue has grown at a -14.9% compound annual rate (a contraction).

Summary generated from market data by MetaCap's automated system. Methodology

Editas Medicine income statement (annual)

Editas Medicine annual income statement
Fiscal year (USD)FY 20252025-12-31FY 20242024-12-31FY 20232023-12-31FY 20222022-12-31FY 20212021-12-31FY 20202020-12-31FY 20192019-12-31FY 20182018-12-31FY 20172017-12-31FY 20162016-12-31
Revenue40.52M32.31M78.12M19.71M25.54M90.73M20.53M31.94M13.73M6.05M
Revenue growth (YoY)+25.39%-58.64%+296.32%-22.83%-71.85%+341.93%-35.71%+132.64%+126.80%—
Operating Expenses200.53M283.47M247.30M245.66M218.69M225.57M161.45M145.66M133.66M103.24M
Research & Development89.95M199.25M177.65M174.96M142.51M158.00M96.90M90.65M83.16M56.98M
Operating Income-160.01M-251.15M-169.18M-225.95M-193.15M-134.84M-140.92M-113.73M-119.93M-97.19M
Interest Expense2.13M0————————
Other Income (Expense)-50.00K14.06M15.96M5.52M644.00K18.86M7.18M3.77M-391.00K5.00K
Income Tax00000—————
Net Income-160.06M-237.09M-153.22M-220.43M-192.50M-115.98M-133.75M-109.95M-120.32M-97.18M
Net Income growth (YoY)——————————
EPS (Basic)-1.80-2.88-2.02-3.21-2.85-1.98-2.68-2.33-2.98-3.02
EPS (Diluted)-1.80-2.88-2.02-3.21-2.85-1.98-2.68-2.33-2.98-3.02
Shares Outstanding (Basic)88.75M82.34M75.97M68.66M67.62M58.61M49.98M47.10M40.32M32.22M
Shares Outstanding (Diluted)88.75M82.34M75.97M68.66M67.62M58.61M49.98M47.10M40.32M32.22M
EBITDA-154.73M-245.34M-163.12M-219.61M-188.09M-130.88M-138.09M-110.47M-117.25M-95.99M
Operating Margin-394.89%-777.22%-216.56%-1146.26%-756.13%-148.61%-686.39%-356.10%-873.64%-1605.62%
Net Margin-395.01%-733.72%-196.13%-1118.26%-753.61%-127.82%-651.43%-344.28%-876.49%-1605.53%

This table shows 10 annual periods of Editas Medicine's income statement, from FY 2025 back to FY 2016, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow EDIT's reporting calendar. What is a income statement?

More financial data